A vaginal microbicide gel meant to protect women from HIV was found to be safe but ineffective in clinical trials, reports Agence France Presse. The gel, titled PRO 2000, was tested at two different concentrations in a trial that enrolled more than 9,000 African women. This summer, researchers announced that a different vaginal gel—one that contained the HIV med tenofovir—successfully cut the risk of HIV infection by 39 percent. That gel, CAPRISA 004, is still undergoing clinical trials.

To read the AFP story, click here.